» Go to news main
Intra‑individual comparison of 18F‑sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC‑A1): a multicentre, phase 3 trial
Congratulations to Dr. Steven Burrell on his latest published article!
Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
François Bénard, Sara Harsini, Don Wilson, Katherine Zukotynski, Gad Abikhzer, Eric Turcotte, Mariève Cossette, Ur Metser, Jonathan Romsa, Montgomery Martin, Colin Mar, Fred Saad, Jean-Paul Soucy, Bernhard J Eigl, Peter Black, Andra Krauze, Steven Burrell, Alan Nichol, Jean-Claude Tardif
The Lancet Oncology Volume 23, Issue 12, December 2022, Pages 1499-1507
"Summary
Background
Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to compare the diagnostic performance of 99mTc-methylene diphosphonate (99mTc-MDP) single-photon emission CT (SPECT) and 18F-sodium fluoride (18F-NaF) PET–CT for the detection of osseous metastases in patients with high-risk prostate or breast cancer.
Recent News
- New interventional radiology suite and hybrid operating room at the Halifax Infirmary
- Nova Scotia gets first‑in‑Canada relocatable MRI
- QEII welcomes the first GE StarGuide SPECT‑CT scanner in Canada.
- The first 68Ga‑PSMA PET scans in Atlantic Canada mark a new era in prostate cancer assessment
- Dr. David Volders awarded the Dr. Charles Lo Prize in Radiology Research
- Radiology Research Day 2024
- Program Administrator Award of Excellence
- Lung Screening Program Launches
Comments
comments powered by Disqus